Document text
Principal Investigator: RICHARD YUQI ZHAO
Organization: UNIVERSITY OF MARYLAND BALTIMORE
Fiscal Year: 2024
Award: $233,250
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 has presented unprecedented challenges due to its rapid
spread, mutability, high death rate, and long-term complications. Vaccines have shown efficacy but wane over
time, and new variants emerge. Antiviral drugs offer an effective alternative, but their success has been variable,
and the development of drug resistance is a concern. Hence, there is a continued need to identify novel antiviral
drugs for the treatment of COVID-19 and its post-COVID complications.
Through a comprehensive genome-wide study utilizing a surrogate fission yeast system, we have identified
the ORF3a protein as a promising therapeutic target. ORF3a is known to play a significant role in viral
pathogenesis, contributing to cellular damage in the lungs and kidneys, induction of the NLRP3 inflammasome
and cytokine storm, and the severity of COVID-19. Specifically, our research demonstrates that ORF3a
expression in lung and kidney epithelial cells induces innate cellular oxidative stress and proinflammatory
immune responses, leading to NF-kB-mediated cytokine production of TNFα and IL-6, ultimately resulting in
apoptotic cell death. We refer to these effects collectively as "the cytopathic ORF3a effects."
Consistent with clinical observations linking the emergence of ORF3a mutants to COVID-19 severity, we have
also observed distinct variations in the cytopathic activities of emerging ORF3a mutants. As oxidative stress and
inflammation contribute to cell death, tissue damage, and the severity of COVID-19, and ORF3a triggers cytokine
storm and upregulation of TNFα and IL-6, which are strong predictors of COVID-19 severity, targeting ORF3a's
cytopathic effects becomes crucial for mitigating the impact of the disease.
The objective of our study is to develop an integrated system utilizing fission yeast and human cells to identify
human suppressive cellular proteins (hSCPs) and small molecule inhibitors (SMIs) that specifically target ORF3a.
Our approach consists of two main aims: (1) conducting a genome-wide search to identify hSCPs capable of
suppressing ORF3a, and (2) employing a fission yeast cell-based high-throughput screening (HTS) system to
rapidly identify SMIs with therapeutic potential. We hypothesize that direct inhibition of ORF3a using an SMI
will effectively counteract its cytopathic effects, mitigate tissue damage, and reduce the severity of COVID-19.
Our research team comprises experts in yeast biology, virology, viral infection in BSL-3 containment, HTS drug
discovery, and medicinal chemistry. The novelty of our project lies in the absence of known inhibitors targeting
ORF3a, underscoring the significance of this study. In our preliminary HTS runs, we have identified a SMI S3080,
an FDA-approved antiviral drug Etravirine, as an inhibitor of ORF3a in both fission yeast and mammalian cells,
thereby supporting the feasibility of our proposed HTS study. Successful completion of this research will enable
the identification of hSCPs and SMIs capable of inhibiting the cytopathic effects of ORF3a, thereby laying the
foundation for the development of effective antiviral drugs against COVID-19.
Terms: <(TNF)-α><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Anti-viral Agents><Apoptotic><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Biologic Models><Biological Models><Biology><Body Tissues><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 severity><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID-19 years><COVID19 disease severity><COVID19 severity><COVID19 virus><CV-19><Cachectin><Cell Body><Cell Death><Cells><Cellular injury><Clinical><CoV-2><CoV2><Containment><Coronavirus Infectious Disease 2019><Death Rate><Development><Disease><Disorder><Drugs><Effectiveness><FDA approved><Fission Yeast><Foundations><Goals><HPGF><Hepatocyte-Stimulating Factor><High Throughput Assay><Human><Human Cell Line><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune response><Immunoglobulin Enhancer-Binding Protein><Immunological response><Infection><Inflammasome><Inflammation><Inflammatory><Interleukin-6><Kidney><Kidney Urinary System><Lead><Link><Long COVID><Long COVID-19><Long coronavirus disease><Long coronavirus disease 2019><Lung><Lung Respiratory System><MGI-2><Macrophage-Derived TNF><Mammalian Cell><Mediating><Medication><Medicinal Chemistry><Medicine><Model System><Modern Man><Molecular><Monocyte-Derived TNF><Myeloid Differentiation-Inducing Protein><NF-kB><NF-kappa B><NF-kappaB><NFKB><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Oxidative Stress><Pathway interactions><Pb element><Persons><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Plasmacytoma Growth Factor><Play><Process><Production><Proteins><Research><Role><Running><S pombe><S. pombe><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CO-V2><SARS-COVID-2><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Schizosaccharomyces pombe><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Specialist><Structure-Activity Relationship><System><Systems Integration><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Testing><Therapeutic><Time><Tissues><Transcription Factor NF-kB><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Up-Regulation><Upregulation><Vaccines><Variant><Variation><Viral><Viral Diseases><Viral Pathogenesis><Virus Diseases><Wuhan coronavirus><Yeasts><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral development><antiviral drug development><antiviral therapeutic development><antiviral therapy development><cDNA Library><cell damage><cell injury><cellular damage><chemical structure function><chronic COVID><chronic COVID-19><chronic complication of COVID-19><chronic novel coronavirus disease 2019><clinical relevance><clinically relevant><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><cytokine release syndrome><cytokine storm><damage to cells><develop drug resistance><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><drug detection><drug discovery><drug resistance development><drug testing><drug/agent><emergent virus><emerging virus><experience><genome scale><genome wide analysis><genome wide studies><genome-wide><genome-wide analysis><genome-wide identification><genomewide><hCoV19><heavy metal Pb><heavy metal lead><high throughput screening><high-throughput drug screening><host response><immune system response><immunoresponse><inhibitor><injury to cells><insight><integrated system><interferon beta 2><kappa B Enhancer Binding Protein><kidney epithelial cell><long haul COVID><long haul COVID-19><long haul coronavirus disease><long haul coronavirus disease 2019><long-hauler COVID><long-hauler COVID-19><long-hauler coronavirus disease 2019><long-hauler syndrome><long-term COVID><long-term COVID-19><long-term coronavirus disease><long-term coronavirus disease 2019><longterm COVID><longterm COVID-19><longterm coronavirus disease><longterm coronavirus disease 2019><mortality rate><mortality ratio><mutant><nCoV2><necrocytosis><novel><nuclear factor kappa beta><pathway><persistent COVID-19><post COVID syndrome><post COVID-19 complications><post COVID-19 related complications><post COVID-19 syndrome><post acute COVID syndrome><post acute COVID-19><post acute COVID-19 syndrome><post acute SARS-CoV-2><post acute coronavirus disease 2019><post acute coronavirus disease 2019 syndrome><post acute coronavirus disease syndrome><post acute severe acute respiratory syndrome coronavirus 2><post coronavirus disease 2019 syndrome><post coronavirus disease syndrome><post-acute phases of COVID-19><prevent><preventing><prolonged COVID-19 symptoms><pulmonary><renal><screening><screenings><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><small molecular inhibitor><small molecule inhibitor><social role><structure function relationship><success><system integration><therapeutic target><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral emergence><viral infection><virology><virus infection><virus pathogenesis><virus-induced disease>